Biotech Losers: Egalet Corp (NASDAQ:EGLT), Marina Biotech (OTCMKTS:MRNA), Conatus Pharmaceuticals (NASDAQ:CNAT), Acceleron Pharma (NASDAQ:XLRN)

Egalet Corporation (NASDAQ:EGLT) announced that its fourth quarter and year ended December 31, 2013 financial results will be released on Wednesday, March 26, 2014. Egalet Corp (NASDAQ:EGLT) stock performance was -5.53% in last session and finished the day at $17.41. Traded volume was 82,789.00 shares in the last session and the average volume of the stock remained 196,859.00 shares. The beta of the stock remained N/A. Egalet Corp (NASDAQ:EGLT) insider ownership is 32.00%.

Marina Biotech, Inc. (OTCMKTS:MRNA) which is a small capped drug maker HQ’ed in Bothell has been in the news last week for two reasons. One is the update it provided on its roadmap for developing new drugs using its proprietary compounds, and the second is the raising of $6 million in proceeds through the sale of some of its shares. Marina Biotech, Inc. (OTCMKTS:MRNA) dropped -7.79% to $1.42 yesterday on volume of 174,919.00 shares. The intra-day range of the stock was $1.37 – $1.59. Marina Biotech, Inc. (OTCMKTS:MRNA) has a market capitalization of 12.98 million.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease announced the initiation of a Phase 2 clinical trial of its lead drug candidate, emricasan, in patients with nonalcoholic fatty liver disease (NAFLD), including the subset of NAFLD patients with inflammatory and/or fibrotic nonalcoholic steatohepatitis (NASH). Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)’s stock on March 18, 2014 reported a lower of -5.69% to the closing price of $10.45. Its fifty two weeks range is $5.76 – $15.67. The total market capitalization recorded 121.89 million. The overall volume in the last trading session was 508,521.00 shares. In its share capital, Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has 11.66 million outstanding shares.

Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced that its collaboration partner, Celgene Corporation, will present interim data from an ongoing phase 2a study of sotatercept in patients with end stage renal disease (ESRD) on hemodialysis at the National Kidney Foundation 2014 Spring Clinical Meeting. On Tuesday, shares of Acceleron Pharma Inc. (NASDAQ:XLRN) dropped -5.69% to close the day at $40.08. Company return on investment (ROI) is 11.50% and its monthly performance is recorded as -4.00%. Acceleron Pharma Inc. (NASDAQ:XLRN) quarterly revenue growth is 37.31%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone